Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Stedman

Showing results (111-120 of 124) with videos related to

Pageof 13
Sort By:
Hepatology (Baltimore, Md.)|May 13, 2017
Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimenEdward J Gane, Mitchell L Shiffman, Kyle Etzkorn, et al.
Journal of Pediatric Gastroenterology and Nutrition|December 20, 2024
Determining the time to cholangiocarcinoma in pediatric-onset PSC-IBDBatul Kaj-Carbaidwala, Johan Fevery, Douglas G Adler, et al.
International Journal of Astrobiology|December 4, 2023
Astrovirology: how viruses enhance our understanding of life in the UniverseGareth Trubl, Kenneth M Stedman, Kathryn F Bywaters, et al.
Lancet (London, England)|October 19, 2010
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trialEdward J Gane, Stuart K Roberts, Catherine A M Stedman, et al.
Microbiology Resource Announcements|September 5, 2020
Best Practices for Successfully Writing and Publishing a Genome Announcement in <i>Microbiology Resource Announcements</i>Julie C Dunning Hotopp, David A Baltrus, Vincent M Bruno, et al.
Annals of Internal Medicine|November 10, 2015
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized TrialStephen Pianko, Steven L Flamm, Mitchell L Shiffman, et al.
Biorxiv : the Preprint Server for Biology|December 15, 2025
A geothermal amoeba sets a new upper temperature limit for eukaryotesH Beryl Rappaport, Natalie A Petek-Seoane, Tomáš Tyml, et al.
Gastroenterology|August 4, 2016
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 TrialEdward J Gane, Kris V Kowdley, David Pound, et al.
Mbio|September 3, 2020
Unveiling Crucivirus Diversity by Mining Metagenomic DataIgnacio de la Higuera, George W Kasun, Ellis L Torrance, et al.
The New England Journal of Medicine|July 22, 2015
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1Susanna Naggie, Curtis Cooper, Michael Saag, et al.
Pageof 13

Showing results (111-120 of 124) with videos related to

Sort By:
Pageof 13
Hepatology (Baltimore, Md.)|May 13, 2017
Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimenEdward J Gane, Mitchell L Shiffman, Kyle Etzkorn, et al.
Journal of Pediatric Gastroenterology and Nutrition|December 20, 2024
Determining the time to cholangiocarcinoma in pediatric-onset PSC-IBDBatul Kaj-Carbaidwala, Johan Fevery, Douglas G Adler, et al.
International Journal of Astrobiology|December 4, 2023
Astrovirology: how viruses enhance our understanding of life in the UniverseGareth Trubl, Kenneth M Stedman, Kathryn F Bywaters, et al.
Lancet (London, England)|October 19, 2010
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trialEdward J Gane, Stuart K Roberts, Catherine A M Stedman, et al.
Microbiology Resource Announcements|September 5, 2020
Best Practices for Successfully Writing and Publishing a Genome Announcement in <i>Microbiology Resource Announcements</i>Julie C Dunning Hotopp, David A Baltrus, Vincent M Bruno, et al.
Annals of Internal Medicine|November 10, 2015
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized TrialStephen Pianko, Steven L Flamm, Mitchell L Shiffman, et al.
Biorxiv : the Preprint Server for Biology|December 15, 2025
A geothermal amoeba sets a new upper temperature limit for eukaryotesH Beryl Rappaport, Natalie A Petek-Seoane, Tomáš Tyml, et al.
Gastroenterology|August 4, 2016
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 TrialEdward J Gane, Kris V Kowdley, David Pound, et al.
Mbio|September 3, 2020
Unveiling Crucivirus Diversity by Mining Metagenomic DataIgnacio de la Higuera, George W Kasun, Ellis L Torrance, et al.
The New England Journal of Medicine|July 22, 2015
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1Susanna Naggie, Curtis Cooper, Michael Saag, et al.
Pageof 13